inclusion criteria: 1. willing and able to provide informed consent themselves or through their legally authorized representative. 2. male or female patients, of any race or ethnicity, 18 to 80 years of age, inclusive, on the day of informed consent. racial and ethnic minorities should be included in the study population to the greatest extent possible. 3. laboratory-confirmed sars-cov-2 infection as determined within 14 days of randomization by real time rt-pcr or other commercial or public health assay authorized by fda or other applicable health authority . 4. onset of covid-19 symptoms within 14 days prior to randomization. 5. have at least one of the following symptoms at screening: fever, cough, shortness of breath, myalgia, ageusia, anosmia, fatigue, or weakness. 6. hospitalized with covid-19 disease (who covid-19 clinical improvement ordinal scale score of 3 \[hospitalized, no oxygen therapy\], 4 \[hospitalized, oxygen by mask or nasal prongs\], or 5 \[high-flow oxygen or non-invasive mechanical ventilation\]) 7. patient is aware of the investigational nature of this study and willing to comply with protocol treatments, blood tests, and other evaluations listed in the informed consent form.

inclusion criteria: 1. willing and able to provide informed consent themselves or through their legally authorized representative. 2. male or female patients, of any race or ethnicity, 18 to 80 years of age, inclusive, on the day of informed consent. racial and ethnic minorities should be included in the study population to the greatest extent possible. 3. laboratory-confirmed sars-cov-2 infection as determined within 14 days of randomization by real time rt-pcr or other commercial or public health assay authorized by fda or other applicable health authority . 4. onset of covid-19 symptoms within 14 days prior to randomization. 5. have at least one of the following symptoms at screening: fever, cough, shortness of breath, myalgia, ageusia, anosmia, fatigue, or weakness. 6. hospitalized with covid-19 disease (who covid-19 clinical improvement ordinal scale score of 3 \[hospitalized, no oxygen therapy\], 4 \[hospitalized, oxygen by mask or nasal prongs\], or 5 \[high-flow oxygen or non-invasive mechanical ventilation\]) 7. patient is aware of the investigational nature of this study and willing to comply with protocol treatments, blood tests, and other evaluations listed in the informed consent form.

inclusion criteria: willing and able to provide informed consent themselves or through their legally authorized representative. male or female patients, of any race or ethnicity, 18 to 80 years of age, inclusive, on the day of informed consent. racial and ethnic minorities should be included in the study population to the greatest extent possible. laboratory-confirmed sars-cov-2 infection as determined within 14 days of randomization by real time rt-pcr or other commercial or public health assay authorized by fda or other applicable health authority . onset of covid-19 symptoms within 14 days prior to randomization. have at least one of the following symptoms at screening: fever, cough, shortness of breath, myalgia, ageusia, anosmia, fatigue, or weakness. hospitalized with covid-19 disease (who covid-19 clinical improvement ordinal scale score of 3 [hospitalized, no oxygen therapy], 4 [hospitalized, oxygen by mask or nasal prongs], or 5 [high-flow oxygen or non-invasive mechanical ventilation]) patient is aware of the investigational nature of this study and willing to comply with protocol treatments, blood tests, and other evaluations listed in the informed consent form.

inclusion criteria: willing and able to provide informed consent themselves or through their legally authorized representative. male or female patients, of any race or ethnicity, 18 to 80 years of age, inclusive, on the day of informed consent. racial and ethnic minorities should be included in the study population to the greatest extent possible. laboratory-confirmed sars-cov-2 infection as determined within 14 days of randomization by real time rt-pcr or other commercial or public health assay authorized by fda or other applicable health authority . onset of covid-19 symptoms within 14 days prior to randomization. have at least one of the following symptoms at screening: fever, cough, shortness of breath, myalgia, ageusia, anosmia, fatigue, or weakness. hospitalized with covid-19 disease (who covid-19 clinical improvement ordinal scale score of 3 [hospitalized, no oxygen therapy], 4 [hospitalized, oxygen by mask or nasal prongs], or 5 [high-flow oxygen or non-invasive mechanical ventilation]) patient is aware of the investigational nature of this study and willing to comply with protocol treatments, blood tests, and other evaluations listed in the informed consent form.

inclusion criteria: 1. willing and able to provide informed consent themselves or through their legally authorized representative. 2. male or female patients, of any race or ethnicity, 18 to 80 years of age, inclusive, on the day of informed consent. racial and ethnic minorities should be included in the study population to the greatest extent possible. 3. laboratory-confirmed sars-cov-2 infection as determined within 14 days of randomization by real time rt-pcr or other commercial or public health assay authorized by fda or other applicable health authority . 4. onset of covid-19 symptoms within 14 days prior to randomization. 5. have at least one of the following symptoms at screening: fever, cough, shortness of breath, myalgia, ageusia, anosmia, fatigue, or weakness. 6. hospitalized with covid-19 disease (who covid-19 clinical improvement ordinal scale score of 3 [hospitalized, no oxygen therapy], 4 [hospitalized, oxygen by mask or nasal prongs], or 5 [high-flow oxygen or non-invasive mechanical ventilation]) 7. patient is aware of the investigational nature of this study and willing to comply with protocol treatments, blood tests, and other evaluations listed in the informed consent form.

inclusion criteria: 1. willing and able to provide informed consent themselves or through their legally authorized representative. 2. male or female patients, of any race or ethnicity, 18 to 80 years of age, inclusive, on the day of informed consent. racial and ethnic minorities should be included in the study population to the greatest extent possible. 3. laboratory-confirmed sars-cov-2 infection as determined within 14 days of randomization by real time rt-pcr or other commercial or public health assay authorized by fda or other applicable health authority . 4. onset of covid-19 symptoms within 14 days prior to randomization. 5. have at least one of the following symptoms at screening: fever, cough, shortness of breath, myalgia, ageusia, anosmia, fatigue, or weakness. 6. hospitalized with covid-19 disease (who covid-19 clinical improvement ordinal scale score of 3 [hospitalized, no oxygen therapy], 4 [hospitalized, oxygen by mask or nasal prongs], or 5 [high-flow oxygen or non-invasive mechanical ventilation]) 7. patient is aware of the investigational nature of this study and willing to comply with protocol treatments, blood tests, and other evaluations listed in the informed consent form.